BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)

BMO Capital analyst Etzer Darout reiterated an Outperform rating and $58.00 price target on Merus N.V. (NASDAQ: MRUS).

The analyst commented, "ASCO abstracts have been released for MRUS (a Top Pick) including data for petosemtamab, MCLA-145, and MCLA-129. The petosemtamab in 1L head and neck cancer is the headline with petosemtamab + pembrolizumab combination delivering a 60% ORR, albeit in 10 patients and limited median follow-up (1.35 mo). The response rate is consistent with our upside case and management will present a more mature clinical update from a later cutoff date on 5/28 "where the response rate further improved" per the press release. Reiterate OP and Top Pick status."

For an analyst ratings summary and ratings history on Merus N.V. click here. For more ratings news on Merus N.V. click here.

Shares of Merus N.V. closed at $44.07 yesterday.

You May Also Be Interested In

• Baldwin Insurance (BWIN) PT Raised to $25 at BMO Capital
• Alaska Air (ALK) PT Raised to $62 at UBS on Updated Q2 Estimates
• BMO Capital on Pfizer (PFE): 'SigVie Trial Misses on OS With Signs of Benefit for Future Trials'